APP download


Tel: +86-571-89360709  E-mail:
Address: 21-23, Health Valley, No. 1500, Wenyi West Road, Yuhang District, Hangzhou, Zhejiang, China
Copyright: Hangzhou Repugene Technology Co., Ltd.   Powered by  

Hangzhou Repugene Technology Co., Ltd.  is a high-tech advanced biomedical research and development enterprise with the team of Dr. Haigui.



Each cell is unique, but most of the current research is directed at cell populations (such as whole tissue), ignoring the heterogeneity between cells. Single-cell sequencing is a new technology for simultaneous high-throughput sequencing of genomic, transcriptome, and epigenetic groups at the single cell level for up to tens of thousands of cells. Single-cell sequencing can more accurately analyze the difference between cells and cells, and realize the genetic detection from the "average value" to the "individual value", which is called the technology of gene sequencing 2.0 era. After the analysis, from the "individual value" to the "group value", it is possible to classify similar cell populations, count each type of cells and analyze their proportion and status in the population, which is a powerful clinical study and The platform for basic research.
Dry goods|What you want to know about
Today, the Rip Gene Harvesting Newsletter, Ripple Medical Laboratory conducted the "2018 National High-throughput Sequencing and Detection of Tumor Mutations in Tumors" by the Health and Medical Research Center.
Happy news! Accurate and standard counterparts, Ripple's full score through the national tumor somatic mutation high-throughput
EGFR mutation is one of the important mechanisms of non-small cell lung cancer (NSCLC). The NCCN guidelines clearly indicate that there is a significant correlation between EGFR mutation and patient sensitivity to tyrosine kinase inhibitors. It is strongly recommended to perform mutation detection during diagnosis and treatment. EGFR mutations mainly occur in exons 18-21, of which 19 exon deletion mutations and exon 21 L858R mutations account for more than 80% of all EGFR mutations, which are common pathogenic mutations.
Case Study|Rip detection found a rare mutation in EGFR to expand the EGFR-TKI mutation spectrum
Rip Gene was invited to participate in the 2018 Annual Meeting of the Lung Cancer Professional Committee of the Hebei Anti-Cancer Association, the 2018 Annual Meeting of the Thoracic Surgeon Branch of the Hebei Provincial Doctors Association and the Inaugural Meeting of the Lung Cancer Professional Committee of the Hebei Cancer Prevention and Control Federation, which attracted great attention from the industry! The conference focused on basic research on lung cancer and esophageal cancer, and attracted many clinical caffes to enter the academic feast, and conducted in-depth exchanges and discussions on the latest clinical diagnosis and treatment standards. The conference was held in Shijiazhuang, Hebei Province!
Accurate medical treatment, testing first--Rip gene was invited to appear at the 2018 annual meeting of the Hebei Provincial Ant
Changan looked back and embroidered into piles, and the top of the mountain was opened. With its profound heritage, Chang'an City carries the praise of the literati and the vicissitudes of modern civilization. On December 12, Changan Hospital and Rip Gene and Jiaotong University First Affiliated Hospital jointly established a collaboration meeting in Changan Hospital. In the meeting, Changan Hospital and Rip Gene officially signed a strategic cooperation agreement!
Accurate testing guides accurate diagnosis and treatment | Changan Hospital, Ripgen gene signed agreement, reached a deep strate
Lung cancer is the most common malignancy worldwide. According to statistics, in 2015, the number of new cases of lung cancer and deaths in China were 733,300 and 610,200, respectively, which is the highest malignant tumor with the highest morbidity and mortality in China. About 80% to 85% of lung cancer patients are non-small cell lung cancer (NSCLC). The pathogenesis of NSCLC includes EGFR mutation, ALK fusion, ROS1 fusion and other driving mechanisms. Elucidation of the pathogenesis of lung cancer is conducive to the precise treatment of patients, such as patients with EGFR activating mutations have a good effect on targeted drugs such as Kamena.
Case Study|Rip gene discovers new pathogenesis of lung cancer
Page up